“Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma” has been added to your cart. View cart

Article: Acalabrutinib, a next-generation Bruton’s tyrosine kinase inhibitor

€3.03

SKU: product-article-41681 Category: General

Description
Reviews (0)

Description

Acalabrutinib, a next-generation Bruton’s tyrosine kinase inhibitor

Reviews

There are no reviews yet.

Be the first to review “Article: Acalabrutinib, a next-generation Bruton’s tyrosine kinase inhibitor”

You must be logged in to post a review.

Top

Article: Acalabrutinib, a next-generation Bruton’s tyrosine kinase inhibitor

Description

Reviews

Related products

Article: Highlights in digestive oncology

Article: INTRODUCTION

Article: Highlights in respiratory oncology

Article: Highlights in squamous cell carcinoma of the head and neck